Sunday, November 8, 2026

EUR/CHF Over 1% Down In The Last 21 Sessions

EUR/CHF Over 1% Down In The Last 21 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.92% for the last 21 sessions. At 17:07 EST on Friday, 28 July, EUR/CHF (EURCHF) is $0.96.

EUR/CHF's yearly highs and lows, it's 1.644% up from its 52-week low and 5.081% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.23%, a negative 0.13%, and a positive 0.22%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.23% (last week), 0.20% (last month), and 0.22% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy technical analysis: the control of the bulls is still remaining - 27 July 2023. According to DailyForex on Thursday, 27 July, "The selling operations that took place in the recent trading sessions did not remove the USD/JPY currency pair from the opportunity to rise so far. ", "The USD/JPY may remain in a narrow range until the reaction to the results of the US economic data today and then the announcement of the policy of the Japanese central bank tomorrow, Friday. "
  • Usd/jpy struggles to gain near the 140.00 mark, investors await US GDP. According to FXStreet on Thursday, 27 July, "Investors will monitor this development and find opportunities around the USD/JPY pair.", "The USD/JPY pair remains under pressure and struggles to gain above the 140.00 mark heading into the early European session on Thursday. "
  • Usd/jpy can push back to the recent high at 145 on no change in the boj's YCC policy – ING. According to FXStreet on Thursday, 27 July, "If the BoJ decides to leave the current policy settings unchanged, then USD/JPY looks as though it can push back to the recent high at 145.", "If the BoJ surprises the market with a YCC tweak as we forecast, or gives a hint of possible policy adjustment in the near future, then USD/JPY could break lower - perhaps even lower than the recent low of 137 as the market would be taken by surprise. "
  • Usd/jpy remains depressed near weekly low, below 141.00 mark as traders await FOMC. According to FXStreet on Wednesday, 26 July, "Investors will look for cues about the future rate-hike path, which, in turn, will play a key role in influencing the USD price dynamics and provide some meaningful impetus to the USD/JPY pair. ", "This, along with the risk-on mood, should cap the safe-haven JPY and lend support to the USD/JPY pair."
  • Usd/jpy sticks to modest intraday gains just below mid-140.00s, focus shifts to US GDP. According to FXStreet on Thursday, 27 July, "The USD/JPY pair attracts some buying during the Asian session on Thursday and reverses a part of the previous day's slide to the weekly low touched in the aftermath of the highly-anticipated FOMC decision. ", "This, in turn, is seen lending some support to the US Dollar (USD) and acting as a tailwind for the USD/JPY pair."

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com